ライフサイエンスコーパス: transplant glomerulopathy

1 d to eventual glomerular destabilization and transplant glomerulopathy.

2 gs were compared with 51 human biopsies with transplant glomerulopathy.

3 n in humans and of a special subset of human transplant glomerulopathy.

4 diated rejection with glomerular thrombi and transplant glomerulopathy.

5 dies, antibody-mediated rejection, and early transplant glomerulopathy.

6 as associated with more rapid progression to transplant glomerulopathy.

7 , or with podocyte depletion associated with transplant glomerulopathy.

8 ortantly, preventing ABMR and development of transplant glomerulopathy.

9 ctomy plus eculizumab patients had almost no transplant glomerulopathy.

10 body-mediated rejection (AMR) and subsequent transplant glomerulopathy.

11 rveillance and clinical biopsies that had no transplant glomerulopathy.

12 several cohorts of patients with and without transplant glomerulopathy.

13 ith scores indicative of fibrosis/atrophy or transplant glomerulopathy.

14 o non-HLA antibodies common to patients with transplant glomerulopathy.

15 fter transplant and strongly associated with transplant glomerulopathy.

16 prognostic features associated with cases of transplant glomerulopathy.

17 ongly predicts graft loss when combined with transplant glomerulopathy.

18 rulosclerosis, fibrointimal hyperplasia, and transplant glomerulopathy.

19 ously reported association of HCV with acute transplant glomerulopathy.

20 he predominant form of glomerular injury was transplant glomerulopathy.

21 l fibrosis and tubular atrophy (IFTA) and by transplant glomerulopathy.

22 glomerular thrombotic microangiopathy (4/4), transplant glomerulopathy (3/4), focal segmental glomeru

23 Transplant glomerulopathy, a common glomerular lesion ob

24 ely for surgical reasons and one failed from transplant glomerulopathy after 5.8 yr with no histologi

25 Missing self associated with transplant glomerulopathy after MVI (HR, 2.51; 95% CI, 1

26 ts were found in 8 of 51 human biopsies with transplant glomerulopathy after rigorous exclusion of im

27 proliferative changes and matrix remodeling (transplant glomerulopathy and capillaropathy); (b) EC pr

28 duction of VEGFA transcripts correlated with transplant glomerulopathy and glomerular thrombotic micr

29 ve means of identifying patients at risk for transplant glomerulopathy and graft loss.

30 Coupled with absent transplant glomerulopathy and low rates of progressive I

31 cytokines in renal allograft recipients with transplant glomerulopathy and seem to be under the regul

32 ial C4d staining of glomerular capillaries+, transplant glomerulopathy and vasculopathy scores, DSA s

33 ficant risk for antibody-mediated rejection, transplant glomerulopathy, and allograft loss (P<0.0001)

34 erstitial fibrosis, tubular atrophy, chronic transplant glomerulopathy, and chronic vascular rejectio

35 d examined associations with C4d deposition, transplant glomerulopathy, and graft failure.

36 more inflammation, were more likely to have transplant glomerulopathy, and had worse graft outcome.

37 The combined presence of C4d positivity, transplant glomerulopathy, and serum creatinine of >2.3

38 gic, and histologic parameters revealed five transplant glomerulopathy archetypes characterized by di

39 sy (7/13), and 24% (4/13) of cases developed transplant glomerulopathy (Banff cg score > 0).

40 in Canada who presented with a diagnosis of transplant glomerulopathy (Banff cg score >=1 by light m

41 increase from baseline) or had minimal or no transplant glomerulopathy (Banff cg0-1).

42 HLA-ID LDKTx have less inflammation and less transplant glomerulopathy, but most chronic histologic c

43 HLA-ID LDKTx have less inflammation and less transplant glomerulopathy, but most chronic histologic c

44 Testing for DSA by C1q is more specific for transplant glomerulopathy (C1q: 81%, 95% CI 0.57-0.94; I

45 d a significantly higher prevalence of acute transplant glomerulopathy (Ctrl, 6%; R-HCV, 55%, P<.0001

46 The median time from transplant to transplant glomerulopathy diagnosis was 33.18 months.

47 henotype had a higher risk of progression of transplant glomerulopathy during follow-up than patients

48 Transplant glomerulopathy-free survival was also inferio

49 By contrast, patients who developed transplant glomerulopathy had 10- to 20-fold increased l

50 man leukocyte antigens type II (DSA II+) and transplant glomerulopathy has been clearly established,

51 95% CI 0.73-1; C1q: 88%, 95% CI 0.62-0.98), transplant glomerulopathy (IgG: 100%, 95% CI 0.73-1; C1q

52 vels of these cytokines were associated with transplant glomerulopathy (IL-1beta, P=0.019; IL-6, P=0.

53 There was no transplant glomerulopathy in biopsies from either group.

54 strongly associated with the development of transplant glomerulopathy in independent validation sets

55 noproliferative glomerulonephritis and acute transplant glomerulopathy in transplanted kidneys.

56 552 biopsy samples (from 385 patients) with transplant glomerulopathy (incidence of 6.7%).

57 Transplant glomerulopathy increased over time after tran

58 dney allograft dysfunction, characterized by transplant glomerulopathy involving glomerular endotheli

59 Transplant glomerulopathy is associated with poor progno

60 A ABMR displayed increased proteinuria, more transplant glomerulopathy lesions, and lower glomeruliti

61 eat transplantation, mean arterial pressure, transplant glomerulopathy, microcirculation inflammation

62 ular injury (n = 2), infarction (n = 1), and transplant glomerulopathy (n = 1).

63 Morphologic criteria for acute transplant glomerulopathy or proliferative glomeruloneph

64 litis was associated with the development of transplant glomerulopathy (OR=10.7, 95% CI=3.1-37.1, P<0

65 Patients who had no C4d deposition, transplant glomerulopathy, or microcirculation inflammat

66 CL2: Cr was significantly higher in IF+i and transplant glomerulopathy patients compared with normal

67 eloped de novo donor-specific antibodies and transplant glomerulopathy showed higher risk of graft lo

68 Kidney transplant (KTx) biopsies showing transplant glomerulopathy (TG) (glomerular basement memb

69 XM) kidney transplant recipients who develop transplant glomerulopathy (TG) and those who do not.

70 Graft survival and time to transplant glomerulopathy (TG) development were estimate

71 Transplant glomerulopathy (TG) is a diagnostic criterion

72 Transplant glomerulopathy (TG) is a histopathologic enti

73 Transplant glomerulopathy (TG) is a major cause of late

74 However, the Banff transplant glomerulopathy (TG) scoring system (chronic g

75 ing precedes and predicts the development of transplant glomerulopathy (TG).

76 r and peritubular capillary inflammation and transplant glomerulopathy (TG).

77 ar factors associated with allograft loss in transplant glomerulopathy (TGP) patients.

78 C4d positivity and transplant glomerulopathy together portended exceptional

79 Transplant glomerulopathy (TxGN; cg>/=1) developed in 47

80 Probable AMR had a higher five-year risk of transplant glomerulopathy vs no AMR (sHR, 4.29; 0.92-19.

81 Transplant glomerulopathy was diagnosed by surveillance

82 Transplant glomerulopathy was diagnosed in 73 patients (

83 Transplant glomerulopathy was present in 25.0% of biopsi

84 pathophysiologic mechanisms associated with transplant glomerulopathy, we examined the expression of